CHRISTIAN ROCK CAFE

[shaneyboy]

NNBP news


Nanobac Life Sciences, Inc. is Cleared to OTC Bulletin Board
Monday November 22, 9:53 am ET


TAMPA, Fla.--(BUSINESS WIRE)--Nov. 22, 2004--Nanobac Life Science, Inc. (OTCBB:NNBP - News), is pleased to announce that on November 18, 2004, NASD cleared ThinkEquity Partners' request for listing on the OTC Bulletin Board for Nanobac Life Sciences, Inc. Common Stock. This marks a milestone in the Company's goal to be in compliance with SEC regulations.
Commenting on the clearance, John Stanton, Chairman and CEO, stated: "We are very pleased that the NASD has cleared us to the OTC Bulletin Board. This clears the way for a new group of investors who have shown great interest in the Company, but have been unable to invest to this point. Further, we will work to create greater awareness of our underlying core technologies and value to the institutional market place."

About Nanobac Life Sciences

Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of Nanobacterium sanguineum (Nanobacteria). The Company's pioneering research is establishing the pathogenic role of Nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to treat nanobacterial infection. The Company currently markets a patented nanobiotic regimen. For further information concerning our nanobiotic, please visit http://www.nanobacsciences.com.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com.

About ThinkEquity

ThinkEquity is a research-centric institutional investment bank focused on the growth sectors of the economy. Nanobac has retained ThinkEquity to advise the Company in all financial matters. For more information go to http://www.thinkequity.com.

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.



--------------------------------------------------------------------------------
Contact:
Nanobac Life Sciences, Inc., Tampa
John Stanton or Alex Edwards, 813-264-2241
or
The Ruth Group
Cynthia Isaac, PhD, 646-536-7028
[e-mail]



--------------------------------------------------------------------------------
Source: Nanobac Life Sciences, Inc.